Objective This study aimed to review the available literatures on control of latent tuberculosis (TB) infection and propose a new control strategy to shorten the course of TB chemotherapy. Data sources The data used in this review were mainly obtained from articles listed in PubMed. The search terms were "therapy (treatment) of tuberculosis," "therapy (treatment) of latent TB infection," and "vaccine of TB." Study selection Articles regarding treatment and vaccine of TB were selected and reviewed. Results The most crucial reason causing the prolonged course of TB chemotherapy is the dormant state of Mycobacterium tuberculosis (M. tuberculosis). Nevertheless, there are, to date, no effective drugs that can directly kill the dormant cells of M. tuberculosis in clinical therapy. In accordance with the growth cycle of dormant M. tuberculosis in the body, the methods for controlling dormant M. tuberculosis include direct killing with drugs, prevention of dormant M. tuberculosis resuscitation with vaccines, and resuscitating dormant M. tuberculosis with preparations or drugs and then thoroughly killing these resuscitated M. tuberculosis by using anti-TB therapy. Conclusions The comprehensive analysis of the above three methods suggests that the drugs directly killing dormant cells are in clinical trials, TMC207 is the most beneficial for controlling TB. Because the side effect of vaccines is less and their action period is long, prevention of dormant cells resuscitation with vaccines is promising. The last control method makes it probable that when a huge number of active cells of M. tuberculosis have been killed and eradicated after 1-month short chemotherapy, only a strong short-term subsequent chemotherapy can completely kill and eradicate the remaining M. tuberculosis. This control strategy is expected to significantly shorten the course of TB chemotherapy and bring a new change and breakthrough in TB treatment.
C urrently, the epidemic situation of tuberculosis (TB) is severe all over the world. In 2012, WHO announced the latest epidemic situation of TB. The number of TB patients increased by 9 000 000, with 1 400 000 patients dying of TB. Drug-resistant TB in China and India accounted for 60% of the worldwide number in 2011. 1 A third of population in the world suffered from latent tuberculosis infection (LTBI). 2 Dormant Mycobacterium tuberculosis (M. tuberculosis) cells under a state of latent infection pose a great danger. On one hand, dormant M. tuberculosis will resuscitate when the body has poor immunity (such as HIV infection, anti-tumor necrosis factor-α therapy), which will finally develop into active TB. On the other hand, latent infection obviously prolongs the course of chemotherapy. In the clinic, long-course chemotherapy can remove most of the M. tuberculosis from TB patients, but a small number of dormant M. tuberculosis will remain in the body, which is the most important reason for recurrent TB. The course of TB chemotherapy is so long, because dormant M. tuberculosis is non-metabolic for a long time and reproduces only when the environment is improved. Because of its non-metabolism or very poor metabolism, chemotherapeutic drugs are useless. Bacillus Calmette-Guérin (BCG) vaccine for prevention of M. tuberculosis in children did not have protective effects on the recurrence of LTBI. 3 Thus, LTBI will probably recur, no matter inoculation with BCG vaccine or not.
When LTBI patients are hypoimmune, dormant cells of M. tuberculosis possibly resuscitate and become active. However, some active M. tuberculosis will also become dormant when the body's immunity recovers to normal. According to the living characteristics of M. tuberculosis in vivo, the methods for controlling dormant M. tuberculosis contain directly killing M. tuberculosis in the latent stage, preventing resuscitation of dormant M. tuberculosis, and actively resuscitating dormant M. tuberculosis prior to thoroughly killing them in a short time. Clinical trials demonstrated that the mortality of TMC207 group (11.4%) was significantly higher than that of the placebo group (2.5%). The reason may probably be that TMC207 induced abnormal electrical activity in the heart and prolonged QT interval and resulted in abnormal cardiac rate and lethal arrhythmia. Taken together, TMC207 should be selectively employed in applicable subjects, and cannot be abused, in order to avoid new drug resistance and severe side effects. 10 
Killing M.tuberculosis in the latent stage

Other potential drugs
In basic experimental studies, some drugs or preparations also presented antibacterial ability against dormant M. tuberculosis. Mitomycin C commonly used for the treatment of hypoxic solid tumors exhibits antibacterial activities against active and dormant M. tuberculosis. Compared with the nitro-containing drugs, mitomycin C had a lower minimum bactericidal concentration.
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Trifluoperazine (a calmodulin inhibitor) and thioridazine are phenothiazine drugs. Trifluoperazine inhibited the growth of M. tuberculosis and multidrug-resistant M. tuberculosis, whether in the active or dormant phases. 12, 13 Thioridazine had antibacterial effects on dormant M. tuberculosis in vitro in Wayne and murine models of dormant M. tuberculosis. 12, 13 In summary, the drugs that directly kill dormant M. tuberculosis can thoroughly sterilize. In particular, TMC207 can kill active and dormant drug-resistant M. tuberculosis. With drug-resistant M. tuberculosis increasing, TMC207 is beneficial in controlling TB. However, whether these drugs can be used in the clinic still requires further clinical investigations.
Killing active M. tuberculosis in the latent phase
In LTBI patients with normal immunity, the dormant M. tuberculosis can resuscitate and become active when the microenvironment is improved. Moreover, the active M. tuberculosis in the body can gradually become dormant with granuloma formation, hypoxia, acidification, or nutrition deficiency. Dormant and active M. tuberculosis coexist in the body of patients, with latent infection or active TB. The biggest difference between active and patent phases is the proportion of dormant and active M. tuberculosis. Therefore, to thoroughly scavenge M. tuberculosis, long-course combined chemotherapy of isoniazid and rifampicin is clinically utilized to kill active M. tuberculosis and resuscitated M. tuberculosis after the microenvironment is improved (in fact, also active M. tuberculosis). Nevertheless, the resuscitation of dormant M. tuberculosis depends on natural improvement in the microenvironment (it is called passive resuscitation), so it is hard to identify the time of resuscitation. Moreover, dormant M. tuberculosis cannot totally resuscitate. Thus, it is difficult to implement a standard medication. This method takes a long time to treat TB. Presently TB chemotherapy is mainly isoniazid-based regimens for 6-9 months. Well-known therapeutic regimens are listed in Table 1 tuberculosis enter the state of dormancy and keep a balance with body's immunity and diminish the incidence of active TB. 16 To some extent, the number of LTBI was increased, but dormant cells of M. tuberculosis were not basically controlled.
Vaccines in post-infective period
These vaccines mainly used for dormant M. tuberculosis of the latent stage can enhance the removal ability of the body against dormant M. tuberculosis. However, the M. tuberculosis in dormant state does not metabolize and is not sensitive to drugs or tolerant to body's immunity. Thus, it is hard to thoroughly scavenge dormant M. tuberculosis with vaccines. We have to enhance the body's immunity in this stage so as to prevent the resuscitation of dormant M. tuberculosis and to keep them dormant all the time.
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Vaccines in multiple stages
Those patients who were infected with M. tuberculosis and injected pre-infection vaccines easily experienced latent infection. Latent infection also requires the injection of vaccines. Thus, researchers designed a vaccine containing protein or its DNA with antigenicity aimed at these two stages, that is, multi-stage vaccine. At present, two multistage vaccines (Hybrid 56 in IC31 and ID93 in GLA-SE) are in Phase I clinical trials. 19 It is hoped that these vaccines can prevent infection of M. tuberculosis and the resuscitation of dormant M. tuberculosis by inducing strong immunity, to succeed in controlling dormant M. tuberculosis.
Therapeutic vaccines
Three kinds of therapeutic vaccines are in clinical trials (heat-inactivated Mycobacterium vaccae vaccine, Mycobacterium indicus pranii, and RUTI). Heatinactivated M. vaccae vaccine is mainly utilized to prevent the occurrence of TB in HIV-infected patients. A majority of TB patients with HIV infection can suffer from LTBI. Therefore, it is significant to control LTBI with heatinactivated M. vaccae vaccine through lowering the incidence of TB in HIV-infected patients. This vaccine is in Phase III clinical trials. 19 RUTI is the only vaccine containing latent antigen. Our early experiments confirmed that RUTI has the potential to treat LTBI through local accumulation of specific CD8 T cells and a strong humoral response in experimental models of mice and guinea pigs after a short period of chemotherapy. The safety of three different doses (5, 25, and 50 μg) of RUTI was evaluated. That in HIV + hypoimmunity population and HIVnormal immunity population, subcutaneous injection of RUTI-induced specific cell immunity in the body can be against multiple antigens also was verified. Combining the results from Phase II clinical trials, we finally selected single subcutaneous injection of 25 μg to conduct further investigations concerning the efficiency and safety of RUTI. At present, it is in two Phase III clinical trials (India and South Africa). 20 ,21 It is difficult to predict the time of M. tuberculosis resuscitation, so vaccines or drugs should be given repetitively. In spite of this, the action period of vaccines is long and side effects are less. It is feasible to prevent the resuscitation of dormant M. tuberculosis by using vaccines.
Actively resuscitating dormant M.tuberculosis and killing them
Resuscitating dormant M. tuberculosis with Rpf and then killing these M. tuberculosis As mentioned above, Rpf protein directly added in the medium containing dormant M. tuberculosis can promote the resuscitation of dormant M. tuberculosis in a short time, but a previous study demonstrated that Rpf possibly has dual effects of inducing both resuscitation and dormancy. 24 Therefore, a large number of experiments are needed to seek an optimal concentration of Rpf for resuscitation. Nevertheless, there is no commercial preparation of purified Rpf used in this method. Rpf is only derived from prokaryotic expression in the laboratory, or the culture supernatant of M. tuberculosis in the logarithmic phase of growth is extracted to be used as Rpf mixture. No studies reported that Rpf is successfully used to resuscitate dormant M. tuberculosis in vivo. Thus, administration effects, dosage form, pathways, and doses of Rpf should be studied, and commercial products of Rpf are needed urgently.
Inducing the resuscitation of dormant M. tuberculosis by reducing immunity
Only about 5% LTBI patients suffered from TB. However, LTBI patients who had both HIV infection and diabetes mellitus or received organ transplantation and immunosuppressant therapy had a high risk for active TB. 17 Thus, it is feasible to induce the resuscitation of dormant M. tuberculosis by lowering immunity. At present, two methods can lower immunity.
Resuscitation of dormant M. tuberculosis induced by immunosuppressant
High-dose glucocorticoid and tumor necrosis factor-α inhibitor (infliximab) are commonly used to treat many diseases clinically, such as rheumatoid arthritis and connective tissue diseases. These drugs lower immunity by reducing tumor necrosis factor-α level, which is not good for granuloma formation and maintenance. Glucocorticoid and infliximab improve the microenvironment for dormant M. tuberculosis and induce M. tuberculosis to resuscitate. When immunosuppressant is used, we have to consider two problems: (1) Without effective anti-TB chemotherapy, the decrease in immunity will contribute to the growth and dissemination of M. tuberculosis; (2) The use of highdose glucocorticoid also possibly leads to opportunistic infection. Therefore, it is indispensable to combine anti-TB chemotherapy, and immunosuppressant should be used for short course. 25 If local epidemiological data demonstrated extensively drug-resistant M. tuberculosis, it is not appropriate to prevent M. tuberculosis dormancy or induce the resuscitation of dormant M. tuberculosis by using immunosuppressant.
The use of high-dose glucocorticoid probably leads to edema, hyperglycemia, electrolyte disturbance, or severe hypertension. Inducing the resuscitation of dormant M. tuberculosis by lowering immunity can bring more harm than good to common LTBI patients, which does not obey ethics. Thus, the immunosuppressant therapy for the resuscitation of dormant M. tuberculosis should be used in applicable persons with an appropriate dose and course of therapy. Applicable persons are active TB patients who are undergoing chemotherapy. As mentioned above, active M. tuberculosis will gradually become dormant M. tuberculosis due to strong immunity and granuloma formation in active TB patients, which will affect the therapeutic effect of chemotherapeutic drugs. Nevertheless, at this time, the use of immunosuppressant, which can moderately lower immunity and prevent M. tuberculosis from entering dormancy or induce the resuscitation of dormant M. tuberculosis, and the application of chemotherapeutic drugs simultaneously are expected to noticeably shorten the course of chemotherapy. There are many side effects of the use of glucocorticoid in the whole body. So present studies mainly focused on the application of inhaled glucocorticoid. Tumor necrosis factor-α inhibitor etanercept has been applied in TB combined with HIV infection patients in clinical trials. Etanercept is administered mainly by subcutaneous injection, twice a week, 25 mg once, totally for 4 weeks, and is used on the fourth day of standard anti-TB chemotherapy. 26 Some special LTBI patients, for example, autoimmune disease patients who require immunosuppressant therapy and patients undergoing elective organ transplantation, or HIV infection patients, who have a poor immunity, can receive glucocorticoid or immunosuppressant therapy, These LTBI patients will have a high chance to develop active TB. During immunosuppressant treatment, T-SPOT, TB(+) or PPD(+) patients should receive anti-TB treatment at the same time, which is expected to thoroughly remove M. tuberculosis in a short time when the immunity decreases and dormant M. tuberculosis is resuscitated.
Radiation exposure
When γ ray was exposed to zebrafish infected with latent Mycobacterium marinum (M. marinum) in vitro, dormant M. marinum was resuscitated by reducing immunocytes and lowering the host's immunity. 27 This method cannot be applied in the clinic, but the study of inducing the resuscitation of dormant bacteria using different methods can make us deeply understand the mechanism of the resuscitation of dormant bacteria, which will possibly help in finding the target for preventing or inducing the resuscitation of dormant bacteria.
Effects of mycobacteriophages on inducing the resuscitation of dormant M. tuberculosis
Mycobacteriophages are viruses that infect the mycobacteria. Bioinformatics on phages demonstrated that tape measure proteins at the phage tail contain motif 3, which has peptidoglycan hydrolytic activities as Rpf. 28, 8 Motif 3 possibly has the same effects on the resuscitation of dormant M. tuberculosis as Rpf. Our study used lytic mycobacteriophages containing motif 3 to resuscitate dormant M. tuberculosis in Wayne models. Results showed that mycobacteriophages not only split M. tuberculosis, but also resuscitated dormant M. tuberculosis, and presented increased number of cultured M. tuberculosis and thinned the cell wall of dormant M. tuberculosis.
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Conclusion
In summary, actively resuscitating dormant M. tuberculosis and then killing them in a short time is an ideal method, which can thoroughly clear M. tuberculosis. Combined with effective chemotherapy, it can obviously shorten the course of chemotherapy and reduce recurrence rate. At present, the method that can successfully induce the resuscitation of dormant M. tuberculosis is to lower immunity. The preparations applied in the clinic are glucocorticoid and tumor necrosis factor-α inhibitor. It is important that most LTBI patients do not need inductive treatment. A previous study demonstrated that only 5%-10% patients with M. tuberculosis infection could develop active TB, and 90%-95% LTBI patients with normal immunity would not develop active TB within 50 years. 17 Phage-induced resuscitation of dormant M. tuberculosis is a completely new concept and the study to date is published, so it deserves further investigation.
